Navigation Links
VIVUS to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Dec. 3, 2010 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that senior management will present an overview of the company at two investment conferences during the month of December.The conference presentation schedule is as follows:Canaccord Genuity Cardiovascular, Diabetes & Obesity ConferenceDecember 8, 2010 at 12:30 p.m. PTNikko Hotel, San Francisco, CAPresenter: Charles Bowden, MD, director of clinical development2010 Deutsche Bank BioFEST ConferenceDecember 14, 2010 at 4:05 p.m. ETFour Seasons Hotel, Boston, MAPresenter: Timothy Morris, chief financial officerA live audio webcast and 30-day archive of the presentations will be available at

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development is QNEXA®, which also is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit

CONTACT:   VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officerbkorb@troutgroup.com650-934-5200646-378-2923

Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
7. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
8. VIVUS Announces Sale of MUSE Assets to Meda
9. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
(Date:10/13/2015)... 13, 2015  Synapse Biomedical Inc. ( ) ... (PAS) studying the use of the NeuRx ® ... enroll patients. the United States ... market-approved criteria. The PAS study group met their initial ... study has since expanded the enrollment target to 150 ...
(Date:10/13/2015)... 2015  SeraCare Life Sciences, a leading partner to ... company,s precision medicine business unit has launched its second ... next-generation sequencing (NGS)-based tumor profiling assays.  The Seraseq TM ... mixture of mutations in key oncogenes and tumor suppressor ... , but is offered at five additional allele frequencies. ...
(Date:10/13/2015)... , Oct. 13 2015 ... the addition of the "US & ... 16 Countries (2010-2021)" report to their ... announced the addition of the "US ... - 16 Countries (2010-2021)" report to ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... T-System and Centegra Health System, a ... department visits per year, today announced the successful and rapid deployment of EV™, ... and financial outcomes. , In less than four days, Centegra Hospitals ...
(Date:10/13/2015)... ... ... Tempe Dental Care, a leading Tempe dentists’ office, celebrates offering gentle, pain free sedation ... than 5 years. A leading cause of emergency room visits, school absences, and missed ... , Sedation dentistry provides an anxiety-free dental experience with safe and ...
(Date:10/13/2015)... , ... October 13, 2015 , ... World Patent ... Snow Blanket, a snow melting invention that helps people in clearing snow away from ... will continue to grow at 3.8% per year," says Scott Cooper, CEO and Creative ...
(Date:10/13/2015)... ... October 13, 2015 , ... According to an ESPN ... orbital fracture when a teammate accidentally elbowed him in the left eye during the ... injury is just one of a series of setbacks, including a knee injury that ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... Saye as the newest professional to introduce the latest development, ThermiVa® temperature controlled ... as a leading professional in Obstetrics and Gynecology and a pioneer in the ...
Breaking Medicine News(10 mins):